SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-14-077699
Filing Date
2014-11-06
Accepted
2014-11-06 16:10:51
Documents
6
Period of Report
2014-11-03
Items
Item 2.02: Results of Operations and Financial Condition
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K a14-19949_38k.htm 8-K 23540
2 EX-99.1 a14-19949_3ex99d1.htm EX-99.1 188740
3 GRAPHIC g199493mm01i001.jpg GRAPHIC 5497
4 GRAPHIC g199493mm01i002.jpg GRAPHIC 5502
5 GRAPHIC g199493mm03i001.jpg GRAPHIC 5497
6 GRAPHIC g199493mm03i002.jpg GRAPHIC 5502
  Complete submission text file 0001104659-14-077699.txt   244529
Mailing Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104
Business Address UGLAND HOUSE, SOUTH CHURCH STREET GEORGE TOWN, GRAND CAYMAN E9 KY1-1104 650-808-6000
Theravance Biopharma, Inc. (Filer) CIK: 0001583107 (see all company filings)

IRS No.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36033 | Film No.: 141200767
SIC: 2834 Pharmaceutical Preparations